• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Johnson & Johnson to Test a Pioneering HIV Vaccine: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
July 12, 2019, 4:33 PM ET

Happy Friday, readers!

Johnson & Johnson doesn’t just want to treat HIV—it wants to prevent against it altogether with an experimental vaccine.

The U.S. Drug giant announced Friday that will test out the vaccine in the U.S. And Europe this year, according to CNBC. If it proves successful—following testing on thousands of men who have sex with men—it could become the first approved immunization against the virus.

That would be one of the most significant advances in a field that’s been filled with milestones over the past few decades. For instance, biotech Gilead’s Truvada can prevent HIV transmission among those who take the pill regularly by more than 90%, according to clinical trial data.

And earlier this week, Viiv Healthcare—a joint collaboration between J&J, GlaxoSmithKline, and Shionogi in which Glaxo holds a majority stake—said it would launch trials testing the practicality of a once-monthly HIV treatment injection in U.S. Clinics.

Read on for the day’s news, and have a wonderful weekend.

Sy Mukherjee, @the_sy_guy, [email protected]

DIGITAL HEALTH

Gene editing, but for Alzheimer's. CRISPR gene editing wunderkind Feng Zhang and his posse are at it again—this time, targeting RNA rather than DNA in, what they say, could one day become a technique used to ward off one of the most insidious diseases around: Alzheimer's. (FierceBiotech)

INDICATIONS

Indivior sinks on opioid treatment generic court ruling. Shares of Indivior sank 3% in Friday trading after a federal appellate court upheld lower court rulings finding that generic makers of the opioid addiction treatment Suboxone did not infringe on a number of Indivior's patents. In a separate case, original Indivior parent Reckett Benckiser paid $1.4 billion to settle allegations of scheming to boost Suboxone sales on Thursday; Indivior has faced similar allegations. (Reuters)

THE BIG PICTURE

California extends health care coverage to undocumented young adults. California Gov. Gavin Newsom this week signed into law legislation that will allow undocumented young adults to access health coverage—making California the first state in the nation to do so. The law focuses on California's Medicaid program, called Medi-Cal, which serves poor and disabled residents. It's an expansion of an existing law signed by former governor Jerry Brown which covered residents under the age of 19; now, all Californians under the age of 25 will be able to access to program irrespective of immigration status. (ABC News)

REQUIRED READING

Here Are the Recession Warning Signals That Have Already Gone Off, by Anne Sraders

Two Decades of Disarray at Deutsche Bank, by Rey Mashayekhi

Here's What Space Tourism Will Feel Like, According to Virgin Galactic's CEO, by Erik Sherman

Accenture's New CEO Takes on Digital Disruption, and Diversity: CEO Daily, by Alan Murray

Find past coverage. Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.